Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: The NEURAPRO randomized clinical trial

JAMA Psychiatry

Volumn 74, Issue 1, 2017, Pages 19-27

  McGorry, Patrick D ^a,b   Nelson, Barnaby ^a,b   Markulev, Connie ^a,b   Yuen, Hok Pan ^a,b   Schäfer, Miriam R ^a,c   Mossaheb, Nilufar ^c   Schlögelhofer, Monika ^c   Smesny, Stephan ^d   Hickie, Ian B ^e   Berger, Gregor Emanuel ^f   Chen, Eric Y H ^g   De Haan, Lieuwe ^h   Nieman, Dorien H ^h   Nordentoft, Merete ⁱ   Riecher Rössler, Anita ^j   Verma, Swapna ^k   Thompson, Andrew ^a,l,m   Yung, Alison Ruth ^a,n,o   Paul Amminger, G ^a,b,c  

^a THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Child and Adolescent Psychiatric Service   (Switzerland)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ Psychiatric Centre Bispebjerg   (Denmark)

^j UNIVERSITY OF BASEL   (Switzerland)

^k INSTITUTE OF MENTAL HEALTH   (Singapore)

^l UNIVERSITY OF WARWICK   (United Kingdom)

^m University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; PLACEBO;

ADULT; ARTICLE; ASIA; AUSTRALIA; BLEEDING; BRIEF PSYCHIATRIC RATING SCALE; COGNITIVE BEHAVIORAL THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOBAL FUNCTIONING: SOCIAL AND ROLE SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT COMPLIANCE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA ASSESSMENT; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; SURVIVAL RATE; YOUNG MANIA RATING SCALE; ADOLESCENT; ADVERSE EFFECTS; CASE MANAGEMENT; CLINICAL TRIAL; COGNITIVE THERAPY; COHORT ANALYSIS; DIETARY SUPPLEMENT; DISEASE COURSE; EARLY INTERVENTION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; CASE MANAGEMENT; COGNITIVE THERAPY; COHORT STUDIES; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EARLY MEDICAL INTERVENTION; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

EID: 85011416514     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.2902     Document Type: Article

References (51)

1. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22(2):283-303.
2. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-370.
3. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60(1):21-32.
4. Fusar-Poli P, Rocchetti M, Sardella A, et al. Disorder, not just state of risk: meta-analysis of functioning and quality of life in people at high risk of psychosis. Br J Psychiatry. 2015;207(3):198-206.
5. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67(2-3):131-142.
6. Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996;30(5):587-599.
7. McGorry PD, Yung AR, Phillips LJ. The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull. 2003;29(4):771-790.
8. Addington J, Cadenhead KS, Cannon TD, etal; North American Prodrome Longitudinal Study. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull. 2007;33(3):665-672.
9. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28-37.
10. Woods SW, Addington J, Cadenhead KS, etal. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35(5):894-908.
11. Klosterkötter J, Ruhrmann S, Schultze-Lutter F, et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry. 2005;4(3):161-167.
12. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction of Psychosis Study. Arch Gen Psychiatry. 2010;67(3):241-251.
13. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70(1):107-120.
14. Berger GE, Wood SJ, Ross M, et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis: a longitudinal MRI/MRS study. Curr Pharm Des. 2012;18(4):570-575.
15. van der Gaag M, Smit F, Bechdolf A, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res. 2013;149(1-3):56-62.
16. McGorry P, Nelson B. Why weneed a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment. JAMA Psychiatry. 2016;73(3):191-192.
17. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry. 2006;40(8):616-622.
18. McGorry PD. Risk syndromes, clinical staging and DSM V: new diagnostic infrastructure for early intervention in psychiatry. Schizophr Res. 2010;120(1-3):49-53.
19. McGorry PD. The next stage for diagnosis: validity through utility. World Psychiatry. 2013;12(3):213-215.
20. McGorry PD. Early clinical phenotypes, clinical staging, and strategic biomarker research: building blocks for personalized psychiatry. Biol Psychiatry. 2013;74(6):394-395.
21. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125(1):54-61.
22. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185:291-297.
23. Morrison AP, French P, Parker S, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull. 2007;33(3):682-687.
24. Morrison AP, French P, Stewart SL, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ. 2012;344:e2233.
25. van der Gaag M, Nieman DH, Rietdijk J, et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull. 2012;38(6):1180-1188.
26. Ising HK, Kraan TC, Rietdijk J, et al. Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE-NL) trial. Schizophr Bull. 2016;42(5):1243-1252.
27. Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146-154.
28. Amminger GP, Schäfer MR, Schlögelhofer M, Klier CM, McGorry PD. Longer-term outcomein the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015;6:7934.
29. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
30. Therapeutic Goods Administration. Note for Guidance on Good Clinical Practice: Annotated With TGA Comments (CPMP/ICH/135/95). Canberra, Australia: Therapeutic Goods Administration. https://www.tga.gov. au/sites/default/files/ich13595an.pdf. Published 2000. Accessed September 12, 2016.
31. Markulev C, McGorry PD, Nelson B, et al. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders [published online August 16, 2015]. Early Interv Psychiatry.
32. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11-12):964-971.
33. Montgomery SA, Asberg M. Anew depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
34. McGorry PD, Nelson B, Amminger GP, etal. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70(9):1206-1212.
35. McGorry PD, Nelson B, Goldstone S. Providing care to young people with emerging risk of psychosis: balancing potential risks and benefits. Clin Pract. 2012;9(6):669-682.
36. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68(4):546-557.
37. Fusar-Poli P, Frascarelli M, Valmaggia L, et al. Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychol Med. 2015;45(6):1327-1339.
38. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
39. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
40. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1983.
41. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
42. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992;149(9):1148-1156.
43. Cornblatt BA, Auther AM, Niendam T, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull. 2007;33(3):688-702.
44. Mossaheb N, Schäfer MR, Schlögelhofer M, et al. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective? Schizophr Res. 2013;148(1-3):163-167.
45. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: a meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220-229.
46. Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res. 2011;132(1):8-17.
47. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull. 2007;33(3):673-681.
48. Wiltink S, Velthorst E, Nelson B, McGorry PM, Yung AR. Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv Psychiatry. 2015;9(3):200-206.
49. James MJ, Sullivan TR, Metcalf RG, Cleland LG. Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients. Br J Nutr. 2014;112(5):812-820.
50. Kraemer HC. Messages for clinicians: moderators and mediators oftreatment outcome in randomized clinical trials. Am J Psychiatry. 2016;173(7):672-679.
51. Rapaport MH, Nierenberg AA, Schettler PJ, et al. Inflammation as a predictive biomarker for response to ω-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2016;21(1):71-79.